U.S. markets open in 9 hours 1 minute

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.63+2.56 (+6.55%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close39.07
Open39.69
Bid34.00 x 1000
Ask47.90 x 1200
Day's Range36.50 - 42.56
52 Week Range22.40 - 48.97
Volume226,601
Avg. Volume254,068
Market Cap1.791B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • C4 Therapeutics to Participate in Upcoming March Investor Conferences
      GlobeNewswire

      C4 Therapeutics to Participate in Upcoming March Investor Conferences

      WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming March investor conferences: Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 11:40 a.m. ETGuggenheim Targeted Protein Degradation Day panel discussion on Tuesday, March 16, 2021 at 10:30 a.m. ET A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. Replays of the webcasts will be archived on the C4T website for at least two weeks following each presentation. About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com. CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com

    • C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
      GlobeNewswire

      C4 Therapeutics to Participate in BMO BioPharma Spotlight Series

      WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the BMO BioPharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies, including a panel discussion, “Ligating” Competitors for Collaboration in the Protein Degradation Space, on Thursday, February 18, 2021 at 10:30 a.m. ET. A recording of the panel discussion will be available for replay four hours following the conclusion of the event and can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. The replay will be archived on the C4T website for at least two weeks following the presentation. About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com. CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com